ATTR amyloidosis in patients undergoing transcatheter aortic valve replacement: from prevalence to hemodynamic consequence.

ATTR amyloidosis in patients undergoing transcatheter aortic valve replacement: from prevalence to hemodynamic consequence. - AMLO-TAVR

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55157

Enrollment

340

Registered

2020-02-06

Start date

2020-10-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tevens aandoeningen van hey myocard (amyloidoseophoping). Amyloidosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Severe symptomatic aortic valve stenosis

Exclusion criteria

Exclusion criteria: - Unable to undergo scintigraphy

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: 1. Prevalence of ATTR, measured by bone scintigraphy, in patients undergoing TAVR. 2. Differences in acute hemodynamic response to TAVR between ATTR and non-ATTR patients.	—

Secondary

Measure	Time frame
1. To determine the influence (relative contribution) of ATTR to the LV dysfunction in patients with AS undergoing TAVR. 2. To determine whether ATTR influences the effectiveness of TAVR treatment on improvement in Quality of Life. 3. To determine whether ATTR influences survival and future hospitalizations rate after TAVR treatment 4. To determine possible predictors of the presence of ATTR, using echocardiography and biomarkers.	—

Measure

Time frame

1. To determine the influence (relative contribution) of ATTR to the LV dysfunction in patients with AS undergoing TAVR. 2. To determine whether ATTR influences the effectiveness of TAVR treatment on improvement in Quality of Life. 3. To determine whether ATTR influences survival and future hospitalizations rate after TAVR treatment 4. To determine possible predictors of the presence of ATTR, using echocardiography and biomarkers.

—

Countries

Netherlands

Outcome results